

For patients with schizophrenia

**EXTEND** their support to two months  
with Abilify Asimtufii® (aripiprazole)<sup>1\*</sup>

\*From once-monthly Abilify Maintena® (aripiprazole)

**Abilify Asimtufii®:**  
**the only every-two-month**  
**LAI with an established**  
**molecule – aripiprazole<sup>1,2</sup>**

The most frequently observed TEAEs reported in  $\geq 5\%$  of patients treated with Abilify Asimtufii® in the 32-week trial were increased weight, injection site pain, akathisia, insomnia, anxiety, headache, schizophrenia and upper respiratory tract infection.<sup>1</sup> For full safety information, please see the Product Information.

LAI, long-acting injectable.

 **AbilifyAsimtufii®**  
(aripiprazole) extended release  
suspension for injection

EVERY TWO MONTHS

For patients who have been stabilised on Abilify Maintena®

## Transitioning to Abilify Asimtufii® is simple – no dose titration required<sup>1</sup>

**Abilify Asimtufii® is provided in a pre-filled syringe<sup>1</sup>**



Administer one injection of Abilify Asimtufii® in place of the next scheduled injection of Abilify Maintena® and continue every two months<sup>1</sup>

MAINTENANCE

DAY 1

MONTH 2

The recommended maintenance dose of Abilify Asimtufii® is 960 mg<sup>1</sup>



Abilify Maintena®  
400 mg



Abilify Asimtufii®  
960 mg



Abilify Asimtufii®  
960 mg

OR

Transition at next  
scheduled dose

Continue every  
two months



Abilify Maintena®  
300 mg



Abilify Asimtufii®  
720 mg



Abilify Asimtufii®  
720 mg

If necessary, patients may be given  
the injection up to two weeks  
before or two weeks after the  
scheduled two-month dose<sup>1</sup>

- If there are adverse reactions with the Abilify Asimtufii® 960 mg dose, reduction to Abilify Asimtufii® 720 mg once every two months should be considered at the time of the next scheduled injection<sup>1</sup>

**Reassure patients they can have appointments  
as often as needed to monitor their progress**

# How should Abilify Asimtufii® be administered?

- Abilify Asimtufii® for intramuscular injection in the gluteal muscle only
- Inject slowly as a single injection




Scan the QR code to watch our administration video

## When is a dose adjustment required?<sup>1</sup>

Dose adjustments for Abilify Asimtufii® are different to Abilify Maintena®

Not required	<p><b>No dose adjustment required in patients with:</b></p> <ul style="list-style-type: none"><li>• Renal impairment</li><li>• Mild or moderate hepatic impairment</li></ul>
Required	<p><b>Adjust dose to 720 mg every two months if patient is:</b></p> <ul style="list-style-type: none"><li>• Taking a strong CYP2D6 inhibitor (e.g. bupropion, fluoxetine, paroxetine, quinidine)</li><li>• Taking a strong CYP3A4 inhibitor (e.g. HIV protease inhibitors, itraconazole, ketoconazole)</li><li>• A poor CYP2D6 metaboliser</li></ul>
Avoid use	<p><b>Avoid use if patient is:</b></p> <ul style="list-style-type: none"><li>• Taking a CYP2D6 inhibitor and CYP3A4 inhibitor</li><li>• Taking a CYP3A4 inducer (e.g. carbamazepine, efavirenz, nevirapine, phenobarbital, phenytoin, primidone, rifampicin, rifabutin, St. John's Wort)</li><li>• A poor CYP2D6 metaboliser taking a CYP3A4 inhibitor</li></ul>

# What happens if a dose of Abilify Asimtufii® is missed?<sup>1</sup>



**PBS Information:** Abilify Asimtufii®: Authority Required (STREAMLINED) Code: 16456 for schizophrenia.

This product is not listed on the PBS for the treatment of bipolar 1 disorder.

Abilify Maintena®: Authority Required (STREAMLINED). Code: 4246 for schizophrenia.

This product is not listed on the PBS for the treatment of bipolar 1 disorder.



Scan for Abilify  
Maintena® Product  
Information.

Please review the Abilify Maintena® Product Information before prescribing, available by calling Lundbeck on 1300 721 277 or scanning the QR code

Please review the Abilify Asimtufii® Product Information before prescribing, available by calling Lundbeck on 1300 721 277

**References:** 1. Abilify Asimtufii® Approved Product Information. 2. Abilify Maintena® Approved Product Information.



Abilify Asimtufii® and Abilify Maintena® are registered trademarks of Otsuka Pharmaceutical Co., Ltd. Otsuka Australia Pharmaceutical Pty Ltd ABN 20 601 768 754. Chatswood NSW 2067. Lundbeck Australia Pty Ltd ABN 86 070 094 290. Ground Floor, 1 Innovation Road, North Ryde NSW 2113. Ph: +61 2 8669 1000, Fax: +61 2 8669 1090, Medical Information: 1300 721 277. AU-ABAS-0002. March 2025. 2007535.